NASDAQ:VVOS - Nasdaq - US92859E2072 - Common Stock - Currency: USD
2.52
+0.22 (+9.57%)
The current stock price of VVOS is 2.52 USD. In the past month the price decreased by -27.79%. In the past year, price decreased by -2.7%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
CI | THE CIGNA GROUP | 12.31 | 91.28B | ||
CVS | CVS HEALTH CORP | 12.1 | 82.77B | ||
DGX | QUEST DIAGNOSTICS INC | 18.89 | 19.37B | ||
LH | LABCORP HOLDINGS INC | 15.38 | 18.75B | ||
FMS | FRESENIUS MEDICAL CARE-ADR | 12.71 | 13.87B | ||
DVA | DAVITA INC | 14.62 | 11.11B | ||
BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 109.42 | 10.53B | ||
CHE | CHEMED CORP | 25.3 | 8.55B | ||
HIMS | HIMS & HERS HEALTH INC | 49.46 | 5.93B | ||
CRVL | CORVEL CORP | 27.43 | 5.89B | ||
GH | GUARDANT HEALTH INC | N/A | 5.63B | ||
OPCH | OPTION CARE HEALTH INC | 26.32 | 5.27B |
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). The company is headquartered in Littleton, Colorado and currently employs 114 full-time employees. The company went IPO on 2020-12-11. The firm calls its solution The Vivos Method. The Vivos Method represents the first clinically effective nonsurgical, noninvasive and nonpharmaceutical solution for treating mild to severe OSA. The Vivos Method includes treatment regimens that employ the proprietary Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient's upper airway and/or palate. The Vivos Method comprises various products and services, including Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, and Vivos Airway Intelligence Service.
VIVOS THERAPEUTICS INC
7921 Southpark Plaza,, Suite 210
Littleton COLORADO US
Employees: 119
Company Website: https://vivos.com/
Investor Relations: https://vivos.com/investor-relations/
Phone: 18669084867
The current stock price of VVOS is 2.52 USD. The price increased by 9.57% in the last trading session.
The exchange symbol of VIVOS THERAPEUTICS INC is VVOS and it is listed on the Nasdaq exchange.
VVOS stock is listed on the Nasdaq exchange.
8 analysts have analysed VVOS and the average price target is 6.43 USD. This implies a price increase of 155% is expected in the next year compared to the current price of 2.52. Check the VIVOS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
VIVOS THERAPEUTICS INC (VVOS) has a market capitalization of 14.84M USD. This makes VVOS a Nano Cap stock.
VIVOS THERAPEUTICS INC (VVOS) currently has 119 employees.
VIVOS THERAPEUTICS INC (VVOS) has a support level at 2.51 and a resistance level at 2.66. Check the full technical report for a detailed analysis of VVOS support and resistance levels.
The Revenue of VIVOS THERAPEUTICS INC (VVOS) is expected to grow by 19.39% in the next year. Check the estimates tab for more information on the VVOS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
VVOS does not pay a dividend.
VIVOS THERAPEUTICS INC (VVOS) will report earnings on 2025-05-12.
VIVOS THERAPEUTICS INC (VVOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.91).
The outstanding short interest for VIVOS THERAPEUTICS INC (VVOS) is 6.35% of its float. Check the ownership tab for more information on the VVOS short interest.
ChartMill assigns a fundamental rating of 3 / 10 to VVOS. While VVOS seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months VVOS reported a non-GAAP Earnings per Share(EPS) of -2.91. The EPS increased by 73.35% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -72.86% | ||
ROE | -140.01% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to VVOS. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 55.48% and a revenue growth 19.39% for VVOS